In cerebral ischemia, altered expression and/or activation of CaMKII has been considered as a critical contributor of ischemia-induced neuronal cell death, and CaMKII activation can be targeted for both pro- or anti-neuroprotective therapies depending on timing and duration of treatments [7, 8]. This evidence concerns the gene CAMK2G and ischemia.